Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin radioimmunotherapy plus BEAM conditioning before ASCT in low‑grade B‑cell lymphoma
2004-004349-16Phase 2Completed
- Sponsor
- Groupe d'Étude des Lymphomes de l'Adulte
- Start
- Jan 2006
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in low-grade B-cell lymphoma, sponsored by Groupe d'Étude des Lymphomes de l'Adulte. Primary endpoints: Overall response rate at day 100 after ASCT and Event-free survival at 2 years. Started Jan 2006; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
low-grade B-cell lymphoma
Beyond the preview
Go deeper on 2004-004349-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004349-16.